Zobrazeno 1 - 10
of 10
pro vyhledávání: '"MJ Gandara-LadronDeGuevara"'
Autor:
Mdp Briceño-Casado, JM Borrero-Rubio, E Rios-Sanchez, Silvia Fénix-Caballero, MJ Gandara-LadronDeGuevara, J Diaz-Navarro, Gil-Sierra, FJ Salmeron-Navas, EJ Alegre-Del Rey, C Palomo-Palomo, C Martinez-Diaz
Publikováno v:
Section 2: Selection, Procurement and Distribution.
Background In clinical practice, dimethylfumarate is considered an alternative at the level of conventional systemic drugs in the first line (cyclosporine, methotrexate, acitretin) for moderate-to-severe plaque psoriasis (PP). Purpose To establish wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bfa9d3e5b3e5b65673acc30e87e6c10
https://doi.org/10.1136/ejhpharm-2019-eahpconf.42
https://doi.org/10.1136/ejhpharm-2019-eahpconf.42
Autor:
Gil-Sierra, M Camean-Castillo, MJ Gandara-LadronDeGuevara, Silvia Fénix-Caballero, JC Garciadeparedes-Esteban, JM Borrero-Rubio, MA Blanco-Castaño, J Diaz-Navarro, EJ Alegre-DelRey, C Martinez-Diaz
Publikováno v:
Patient safety and risk management.
Background Optimisation of treatment for patients with renal insufficiency (RI) is necessary to avoid excessive or insufficient dosing of drugs. Identification and selection of adequate treatments for RI patients is mainly limited by time. Purpose To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b2beb668f9edb199a57320088c3e89e
https://doi.org/10.1136/ejhpharm-2017-000640.577
https://doi.org/10.1136/ejhpharm-2017-000640.577
Autor:
JM Borrero-Rubio, E Rios-Sanchez, JC Armario-Hita, MJ Gandara-LadronDeGuevara, EJ Alegre-DelRey, Silvia Fénix-Caballero, J Diaz-Navarro
Publikováno v:
Clinical pharmacy.
Background Biologic drugs have demonstrated efficacy and safety in the treatment of chronic plaque psoriasis. Frequently, label doses tend to be reduced in clinical practice when a sustained response has been reached. Purpose To assess the effectiven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7279df6abd1736a54743b838eb50d436
https://doi.org/10.1136/ejhpharm-2017-000640.181
https://doi.org/10.1136/ejhpharm-2017-000640.181
Autor:
EJ Alegre-Del Rey, MA Blanco-Castaño, JM Borrero-Rubio, Silvia Fénix-Caballero, M Camean-Castillo, Gil-Sierra, JC Garciadeparedes-Esteban, MJ Gandara-LadronDeGuevara, C Martinez-Diaz, J Diaz-Navarro
Publikováno v:
Clinical pharmacy.
Background Pharmacist interventions are important to improve patient safety, avoid physicians prescriptions errors and reduce unnecessary expenses. Electronic assisted prescription is a differential factor to document pharmaceutical interventions, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::493daaa6b1f17a910011ab49d2bfe7a7
https://doi.org/10.1136/ejhpharm-2017-000640.139
https://doi.org/10.1136/ejhpharm-2017-000640.139
Autor:
M Camean-Castillo, JM Borrero-Rubio, E Rios-Sanchez, J Diaz-Navarro, MJ Gandara-LadronDeGuevara, C Palomo-Palomo, JC Garciadeparedes-Esteban, Silvia Fénix-Caballero, C Martinez-Diaz, Gil-Sierra
Publikováno v:
European Journal of Hospital Pharmacy. 23:A74.1-A74
Background Hepatitis C virus infection is the leading cause of liver cirrhosis, hepatocellular carcinoma and liver transplantation, and is associated with an increasing mortality rate in infected individuals. The availability of direct acting antivir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7c2f3f103f87e03f25a841c8484976b
https://doi.org/10.1136/ejhpharm-2016-000875.167
https://doi.org/10.1136/ejhpharm-2016-000875.167
Autor:
JC Garciadeparedes-Esteban, M Camean-Castillo, D Gil-Sierra, EJ Alegre-Del Rey, C Palomo-Palomo, MA Blanco-Castaño, MJ Gandara-LadronDeGuevara, J Diaz-Navarro, JM Borrero-Rubio, Silvia Fénix-Caballero
Publikováno v:
European Journal of Hospital Pharmacy. 23:A146.1-A146
Background McArthur et al 1 recently reported the results of vemurafenib in BRAF mutation positive melanoma (BRIM-3 study) versus dacarbazine. Difference between medians in overall survival (OS) was 3.9 months (13.6 vs. 9.7, respectively). However, g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26fdb1b3db0cb5d6133c6c318cf53c83
https://doi.org/10.1136/ejhpharm-2016-000875.329
https://doi.org/10.1136/ejhpharm-2016-000875.329
Autor:
J Diaz-Navarro, S Fenix-Caballero, D Gil-Sierra, C Palomo-Palomo, JC GarciaDeParedes-Esteban, M Camean-Castillo M, MA Blanco-Castaño, MJ Gandara-LadronDeGuevara, C Freyre-Carrillo, JM Borrero-Rubio
Publikováno v:
European Journal of Hospital Pharmacy. 23:A103.2-A104
Background Antimicrobial stewardships in hospitals work with healthcare practitioners to help patients receive the most appropriate antimicrobial with the correct dose and duration. Time is one of the main limitations for optimal programme implementa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fb09755f8e3529ca0fcd9ca66f522ed
https://doi.org/10.1136/ejhpharm-2016-000875.234
https://doi.org/10.1136/ejhpharm-2016-000875.234
Autor:
JC Garciadeparedes-Esteban, Silvia Fénix-Caballero, M Camean-Castillo, MA Blanco-Castaño, J Diaz-Navarro, MJ Gandara-LadronDeGuevara, C Martinez-Diaz, C Palomo-Palomo, JM Borrero-Rubio, E Rios-Sanchez
Publikováno v:
European Journal of Hospital Pharmacy. 23:A176.1-A176
Background Due to the recent commercialisation of subcutaneous trastuzumab (Tsc) for the treatment of HER2+ breast cancer, there is an opportunity to minimise costs with a potential significant impact on the public health system. Purpose The objectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4cb94caae134c75459e212aefe890b97
https://doi.org/10.1136/ejhpharm-2016-000875.398
https://doi.org/10.1136/ejhpharm-2016-000875.398
Autor:
MJ Gandara-LadronDeGuevara, J Diaz-Navarro, JM Borrero-Rubio, S Fénix-Caballero, EJ Alegre-DelRey, C Palomo-Palomo, R Castaño-Lara, JF Lopez-Vallejo, E Ríos-Sánchez, MA Blanco-Castaño
Publikováno v:
European Journal of Hospital Pharmacy. 20:A65.1-A65
Background A safety alert about the possibility of a potentially fatal interaction in patients, especially neonates, has been issued by the FDA. Patients treated with ceftriaxone and concomitant total parenteral nutrition (TPN) are at potential risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7983fdc5f069b77d86dc06fe40c3381c
https://doi.org/10.1136/ejhpharm-2013-000276.181
https://doi.org/10.1136/ejhpharm-2013-000276.181
DGI-015 Assessment of the Treatment with a Two-Drug Antiretroviral Regimen: Abstract DGI-015 Table 1
Autor:
J M Borrero Rubio, E Rios-Sanchez, JF Lopez-Vallejo, EJ Alegre-DelRey, MJ Gandara-LadronDeGuevara, MA Marin-Marin, MA Blanco-Castaño
Publikováno v:
European Journal of Hospital Pharmacy. 20:A100.3-A101
Background Antiretroviral treatment with a three drug-regimen is the initial treatment recommended for chronic HIV infection. For various reasons, the combination of three drugs can be modified to a two-drug regimen. Purpose To analyse the change fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::921275d29f55cab5fbb0956287fd3eb2
https://doi.org/10.1136/ejhpharm-2013-000276.281
https://doi.org/10.1136/ejhpharm-2013-000276.281